Nurgul Toktogulova

Nurgul Toktogulova

Auto-generated profile, based on publicly available information

Nurgul Toktogulova

Hospital Therapy, IK Akhunbaev Kyrgyz State Medical Academy, Faculty of General Medicine, Bishkek, Kyrgyzstan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
NTNurgul Toktogulova
Nurgul Toktogulova
MBMatthias Breidert
Matthias Breidert
JEJudith Eschbach
Judith Eschbach
IKIndira Kudaibergenova
Indira Kudaibergenova
UOUulkan Omurzakova
Uulkan Omurzakova
PEPierre Eftekhari
Pierre Eftekhari
The knowledge about the features of energy metabolism in MAFLD in the population living at different climatic and geographic heights is lacking. The goal of this study is to explore the biochemical parameters of blood and erythrocyte energy consumption in patients with MAFLD with and without DM2 living in the low- and moderate-altitude regions of Central Asia. Our study was carried out on patients living in low-altitude mountains: Bishkek, altitude=750–800 m; n=67 (MAFLD with DM 2: n=24; MAFLD without DM2: n=25; control: n=18), and At-Bashy District, Naryn Region, altitude=2046–2300 m; n=58 (MAFLD with DM2: n=28; MAFLD without DM2: n=18; control: n=12). Non-alcoholic fatty liver disease was diagnosed according to history, laboratory tests, liver ultrasound, and exclusion of other liver diseases. The level of liver fibrosis was determined using the FIB-4 score. Blood adenosine 5′-triphosphate (ATP) was determined using the CellTiter-Glo method. Healthy residents living in moderate altitudes have significantly higher levels of cytosolic ATP in their blood (p+≤+0.05) than residents living in low mountains. MAFLD is characterized by an increase in the level of ATP concentration in their blood. ATP concentration decreased significantly in patients with MAFLD with DM2 living in moderate-altitude in comparison to those living in low-altitude mountains. The results suggest that chronic altitude hypoxia leads to a breakdown in adaptive mechanisms of energy metabolism of ATP in patients with MAFLD with type 2 DM.

17 December 2022 in Gaceta Médica de Caracas
Verified
Journal Article
Open access
PDF file
NTNurgul Toktogulova
Nurgul Toktogulova
MBMatthias Breidert
Matthias Breidert
RSRoza Sultanalieva
Roza Sultanalieva
RTRustam Tuhvatshin
Rustam Tuhvatshin
AKAltynai Kazieva
Altynai Kazieva
Today, there is insufficient knowledge about the course of metabolically associated fatty liver disease (MAFLD) in Asian populations living at different altitudes. Our article presents the results of the study of MAFLD in individuals with different body weights in conditions of high-mountain hypoxia. To study the course of MAFLD in lean and obese patients living in the conditions of low and high mountains of Kyrgyzstan. An open comparative study of Asian patients with MAFLD with and without type 2 diabetes mellitus (DM2) living in low and high mountains was performed. In each category of patients, the lean (BMI≤23) and obese (BMI> 23) groups were considered. The anthropometric parameters and biochemical parameters of blood were determined. The liver fibrosis index was calculated using the FIB Score. It was found that residents of the high mountains with MAFLD had a lower BMI compared to the lowlanders. Low blood glucose and HbA1c levels are observed in patients with high BMI living in high altitude areas compared with lowlanders, especially in combination with DM2. In the group of obese patients with MAFLD living in highlands, low total cholesterol, low-density lipoproteins and glomerular filtration rate are observed. A high risk of fibrosis was noted in the group of lean patients in both regions. Our results indicate that the study of the effect of chronic high-altitude hypoxia on the course of MAFLD requires prospective population-based studies.

17 November 2025 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
UOUulkan Omurzakova
Uulkan Omurzakova
MBMatthias Breidert
Matthias Breidert
MDMarkus Donner
Markus Donner
NTNurgul Toktogulova
Nurgul Toktogulova
MMMaria Moldobaeva
Maria Moldobaeva
PEPierre Eftekhari
Pierre Eftekhari
Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, is approved for the treatment of type 2 diabetes mellitus and heart failure. Its known ability to enhance mitochondrial adenosine triphosphate production and improve cardiac function led us to investigate whether blood adenosine triphosphate levels could serve as a predictive biomarker for treatment response. This prospective study included 120 patients from Kyrgyzstan: 49 with type 2 diabetes mellitus, 43 with heart failure, and 28 with both type 2 diabetes mellitus and heart failure. The mean age of the study population was 63.9±7.1 years, with no significant age difference between groups. Patients received oral empagliflozin at a dose of either 10 or 25 mg daily for 12 weeks. Adenosine triphosphate activity was measured in erythrocytes from whole blood samples before and after treatment. In vitro assays were also performed, incubating patient blood samples with empagliflozin at concentrations of 0.1, 1, and 10 µM. In patients with type 2 diabetes mellitus, empagliflozin significantly reduced body mass index (p=0.001), though HbA1c levels remained unchanged. Among heart failure patients, treatment resulted in a significant increase in left ventricular ejection fraction (p=0.028) and a decrease in B-type natriuretic peptide levels (p=0.01). Blood adenosine triphosphate concentrations increased significantly following empagliflozin treatment in both type 2 diabetes mellitus and heart failure groups. Proteomic analysis identified 12 differentially expressed proteins—ADIPOQ, ARG1, CST3, CPPED1, GSTO1, FN1, ITIH4, LCN2, LCP1, MIF, PCMT1, and SERPINA3—that are functionally linked to type 2 diabetes mellitus and/or heart failure pathophysiology. Our data suggest that blood adenosine triphosphate activity may serve as a potential biomarker for clinical response to empagliflozin in patients with type 2 diabetes mellitus and heart failure. Further studies are warranted to validate these exploratory findings and to evaluate the sensitivity, specificity, and predictive value of blood adenosine triphosphate as a biomarker in these populations.

31 March 2023 in Bulletin of Osh State University
Verified
Journal Article
Open access
PDF file
АСАлтынай Садыкова
Алтынай Садыкова
НТНургуль Токтогулова
Нургуль Токтогулова
СТСапарбу Тобокалова
Сапарбу Тобокалова
МКМээржан Кадырбердиева
Мээржан Кадырбердиева
СМСабира Маматова
Сабира Маматова
Статья содержит сообщение об осведомленности врачей о жировом гепатозе среди населения. Объектами исследования было анкетирование врачей для оценки осведомленности врачей о НАЖБП с 15 ноября по 25 ноября 2022 г. Установлено, что у многих пациентов с метаболическим синдромом имеется жировая дистрофия гепатоцитов, а у половины обнаруживается стеатогепатит. Для достоверной оценки теоретической базы об НАЖБП участие врачей было добровольным и анонимным. Были опрошены 40 врачей из города Бишкек и 40 врачей из города Ош. Респонденты самостоятельно заполняли анкеты без участия интервьюера, каждому респонденту были заданы по 15 вопросов, касающихся их знаний о жировом гепатозе. После опроса проведен анализ анкетирования.

16 January 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
NTNurgul A. Toktogulova
Nurgul A. Toktogulova
RSRoza B. Sultanalieva
Roza B. Sultanalieva
RTRustam R. Tuhvatshin
Rustam R. Tuhvatshin
TKTurarbek K. Kaliev
Turarbek K. Kaliev
Aim. To study the peculiarities of lipid metabolism disorders in non-alcoholic fatty liver disease in lean and obese patients in medium altitude conditions. Materials and methods. The study was carried out within the framework of the project Etiopathogenetic features and rates of development of non-alcoholic fatty liver disease (NAFLD) in the conditions of Kyrgyzstan (№ of state registration MHN/TZ-2020-3). An open comparative study of patients with two forms of NAFLD: fatty liver and non-alcoholic steatohepatitis (n=236) living in low mountains (Bishkek, altitude above sea level 750800 m; n=111) and middle mountains (At-Bashy district , Naryn region, height above sea level 20462300 m; n=125) Kyrgyzstan. The average age of the patients was 55.70.95 years. Given that genetic factors may play a role in the development of NAFLD, we analyzed a population represented only by ethnic Kyrgyz. Patients in each group were divided into lean (BMI23) and obese (BMI23) groups. To determine physical activity, a physical activity questionnaire was used, which was compiled on the basis of the materials of the International Physical Activity Prevalence Study www.ipaq.ki.se. Physical examination included measurement of anthropometric parameters (height, body weight, waist circumference), calculation of body mass index (BMI), skeletal muscle mass index (SMM), percentage of body fat. According to the grades of the WHO, the degree of obesity was assessed by BMI for Asians. Blood samples were taken for research in the morning on an empty stomach after at least 12 hours of fasting. The following indicators were determined: glucose, lipid spectrum (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels. The BARD scale was used as a predictor for assessing the development of liver fibrosis in patients with NAFLD. The scoring system included three variables: BMI, AST/ALT, and the presence of DM 2. The diagnosis of NAFLD made on the basis of history, laboratory tests, ultrasound examination of the liver, and exclusion of other liver diseases. The results were analyzed using the SPSS 16.0 statistical software package for Windows. A p-value0.05 was considered statistically significant at the 95% confidence level. Results. It was found that the inhabitants of the middle mountains with NAFLD are represented by a lower BMI relative to the inhabitants of the low mountains. In women, the levels of SMM and the percentage of fat are significantly and statistically significantly correlated (r=-0.971; p0.001), while in men these two indicators are not related. Men showed a trend towards higher percentages of fat, regardless of body weight and region of residence. For women, this indicator was within acceptable limits and did not exceed 31%. There was found a statistically significant difference in total cholesterol levels between low and middle mountain people in the group of obese patients (p0.001) suffering from NAFLD. Statistically significant low ALT indices were revealed in the group of obese patients living in mid-mountain conditions. Conclusion. Taken together, our results suggest that chronic mid-mountain hypoxia may slow down the course of overweight-induced NAFLD.

27 September 2024
Verified
Report
Open access
PDF file
YSYasmin A. Sitabkhan
Yasmin A. Sitabkhan
AAAida Alikova
Aida Alikova
NTNurgul Toktogulova
Nurgul Toktogulova
AZAdema Zholdoshbekova
Adema Zholdoshbekova
WRWendi Delcene Ralaingita
Wendi Delcene Ralaingita
JSJonathan Michael Bradley Stern
Jonathan Michael Bradley Stern
We present the results from an exploratory study that aimed to measure teachers’ specialized knowledge in early mathematics during a pilot of an educational intervention using the Foundational Mathematical Knowledge for Teaching (FMKT) survey. The survey was administered to 323 teachers in the Kyrgyz Republic in 2021. We delve into survey results at two timepoints (pre- and post-intervention) to showcase the areas in which the intervention was successful and identify ongoing challenges in teacher knowledge. We found that the FMKT provided detailed, specific information on teacher learning and is an example of one way to center teacher knowledge in an instructional intervention.